Wave Life Sciences Ltd. Stock

$12.90

4.30% day before yesterday

Nasdaq, Dec 27, 10:00 pm CET

ISIN

SG9999014716

Symbol

WVE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Wave Life Sciences Ltd. Stock price

$12.90

-2.91 18.41% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

-0.58 4.30%

ISIN

SG9999014716

Symbol

WVE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$1.97b
Enterprise Value	$1.69b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	31.55
P/S ratio (TTM) P/S ratio	36.70
P/B ratio (TTM) P/B ratio	13.52
Revenue growth (TTM) Revenue growth	-37.29%
Revenue (TTM) Revenue	$53.61m
EBIT (operating result TTM) EBIT	$-152.05m
Free Cash Flow (TTM) Free Cash Flow	$-143.07m
Cash position	$310.95m
EPS (TTM) EPS	$-1.11
P/E forward	negative
P/S forward	37.11
EV/Sales forward	31.91
Short interest	7.82%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Wave Life Sciences Ltd. Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a Wave Life Sciences Ltd. forecast:

9x Buy

90%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a Wave Life Sciences Ltd. forecast:

Buy

90%

Hold

10%

Analyst Estimates with Stock Price Targets

Financial data from Wave Life Sciences Ltd.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	54 54	37% 37% 100%
- Direct Costs	8.69 8.69	9% 9% 16%
Gross Profit	45 45	41% 41% 84%
- Selling and Administrative Expenses	39 39	21% 21% 73%
- Research and Development Expense	149 149	17% 17% 278%
EBITDA	-143 -143	72% 72% -267%
- Depreciation and Amortization	8.69 8.69	9% 9% 16%
EBIT (Operating Income) EBIT	-152 -152	64% 64% -284%
Net Profit	-143 -143	67% 67% -266%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Wave Life Sciences Ltd. Stock News

Neutral

GlobeNewsWire

●

6 days ago

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual administration

Neutral

GlobeNewsWire

●

13 days ago

Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on ...

Neutral

GlobeNewsWire

●

about one month ago

Wave Life Sciences to Present at Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Jefferies London Healthcare Confer...

More Wave Life Sciences Ltd. News

Company Profile

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Head office	Singapore
CEO	Paul Bolno
Employees	268
Founded	2012
Website	www.wavelifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now